Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
News about Chimerix, Inc. (NASDAQ: CMRX) centers on its work as a biopharmaceutical company developing medicines for patients facing deadly diseases, with a particular focus on rare and high-grade brain tumors. Recent press releases emphasize the company’s lead clinical program, dordaviprone (ONC201), in development for H3 K27M-mutant diffuse glioma.
Investors and followers of CMRX news will find updates on key regulatory milestones, including the U.S. Food and Drug Administration’s acceptance of Chimerix’s New Drug Application for dordaviprone in recurrent H3 K27M-mutant diffuse glioma, Priority Review status, and the assigned PDUFA target action date of August 18, 2025. Company news also highlights Rare Pediatric Disease Designation, Fast-Track Designation, and Orphan Drug Designation for dordaviprone in multiple regions.
Chimerix news releases describe ongoing clinical development activities, such as the Phase 3 ACTION trial in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation, and Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetic data. Additional items include corporate events like participation in oncology and precision medicine forums and updates on equity inducement grants under Nasdaq Listing Rule 5635(c)(4).
Another major theme in recent CMRX coverage is the definitive agreement for Jazz Pharmaceuticals to acquire Chimerix for approximately $935 million in cash. News articles outline the transaction terms, expected closing timing subject to customary conditions, and how dordaviprone would fit within Jazz’s rare oncology portfolio. For readers tracking CMRX, this news stream provides a view into Chimerix’s clinical progress, regulatory interactions, and announced strategic transaction with Jazz.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, has announced it will host a live conference call and audio webcast on August 13, 2024, at 8:30 a.m. ET. The purpose of this event is to report financial results for the second quarter ended June 30, 2024, and provide a business overview.
Interested parties can access the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and referring to conference ID 5436125. A live audio webcast will be available on the Investors' section of Chimerix's website, with an archived version accessible approximately two hours after the event.
Chimerix (NASDAQ: CMRX) announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4) on July 5, 2024. The grants, approved by the Compensation Committee on July 1, 2024, include non-statutory stock options to purchase a total of 120,000 shares of common stock. The stock options have an exercise price equivalent to the closing trading price as of the grant date, a 10-year term, and vest over four years. This includes one-fourth vesting on the first-year anniversary of the hire and the remainder vesting monthly over the next three years. The options are subject to the 2024 Equity Incentive Plan's terms, although granted outside of it. Chimerix focuses on developing medicines for life-threatening diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, announced that CEO Mike Andriole will join a fireside chat at the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 3:00 p.m. ET. An audio webcast will be available on Chimerix's Investor Relations website and archived for 90 days.
Chimerix reported its First Quarter 2024 Financial Results and Operational Update, highlighting the progress of the Dordaviprone (ONC201) ACTION study and the encouraging Phase 1 results of ONC206. The company aims to bring dordaviprone to patients facing H3 K27M-mutant diffuse glioma sooner, focusing on regulatory interactions and provisional registrations for accelerated approval. Chimerix also disclosed a net loss of $21.9 million for Q1 2024, with research and development expenses remaining stable. The company's balance sheet indicates $188.2 million in capital for operations with no outstanding debt.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.